Back to top
more

Nevro (NVRO)

(Real Time Quote from BATS)

$5.39 USD

5.39
412,170

+0.56 (11.59%)

Updated Aug 8, 2024 11:24 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (106 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Earnings Preview: Nevro (NVRO) Q2 Earnings Expected to Decline

by Zacks Equity Research

Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Hold on to Nevro (NVRO) Stock Now

by Zacks Equity Research

Nevro (NVRO) is gaining traction from a fortified international footprint and solid prospects in the SCS market. However, severe rivalry is a lingering woe.

Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?

by Zacks Equity Research

Sector ETF report for XHE

Nevro (NVRO) Down 3.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Nevro (NVRO) Q1 Loss Wider Than Expected, Revenues Down Y/Y

by Zacks Equity Research

Nevro's (NVRO) domestic and international revenues fall year over year in Q1.

Nevro (NVRO) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Nevro (NVRO) delivered earnings and revenue surprises of -119.70% and -6.09%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Nevro (NVRO) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nevro (NVRO) Plagued by Issues in Australia & Stiff Rivalry

by Zacks Equity Research

Nevro's (NVRO) international sales get affected by weakness in Australia.

Nevro (NVRO) Q4 Loss Wider Than Expected, Revenues Beat

by Zacks Equity Research

Nevro's (NVRO) solid domestic and international performance aids Q4 results.

Nevro (NVRO) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Nevro (NVRO) delivered earnings and revenue surprises of -88.24% and 0.53%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Nevro (NVRO) Q4 Earnings Expected to Decline

by Zacks Equity Research

Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nevro (NVRO) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Nevro (NVRO) delivered earnings and revenue surprises of -23.33% and 2.11%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Nevro (NVRO) Q3 Earnings Preview: What to Look Out For

by Zacks Equity Research

Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nevro (NVRO) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Nevro (NVRO) delivered earnings and revenue surprises of -16.67% and -0.03%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

    Is the Options Market Predicting a Spike in Nevro (NVRO) Stock?

    by Zacks Equity Research

    Investors need to pay close attention to Nevro (NVRO) stock based on the movements in the options market lately.

      Should You Buy Nevro (NVRO) Ahead of Earnings?

      by Zacks Equity Research

      Nevro (NVRO) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

        Nevro's (NVRO) Q2 Loss Wider than Expected, Revenues Beat

        by Zacks Equity Research

        Nevro's (NVRO) topline gains on continued global adoption of HF10 therapy. Rising operating expenses are major concerns.

          Should You Buy Nevro (NVRO) Ahead of Earnings?

          by Zacks Equity Research

          Nevro (NVRO) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

            Nevro (NVRO) Surges: Stock Moves 11.4% Higher

            by Zacks Equity Research

            Nevro (NVRO) was a big mover last session, as the company saw its shares rise over 11% on the day.

              Megan Sanks headshot

              Here's Why Shares of Nevro Corp. (NVRO) Jumped Today

              by Megan Sanks

              Shares of Nevro Corp. NVRO) climbed 10% in midday trading Wednesday after the company reported preliminary sales numbers for the second quarter of fiscal year 2017.

                Medical Product Q1 Earnings on May 8: ITGR, OPK & More

                by Zacks Equity Research

                Let's take a look at the major Medical products stocks slated to release their first-quarter 2017 reports on May 8.

                  Indradip Ghosh headshot

                  New Strong Buy Stocks for October 13th

                  by Indradip Ghosh

                  Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday